Head-to-head · Cost-Efficiency Index
NextMeds vs Gala Health
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
NextMeds
Shoppers who will call out and verify the exact price at checkout, given the site shows several different promo numbers at once.
Visit NextMedsGala Health
Women who have already committed to a full year and want one all-doses-included rate — plus, unusually, an HRT and menopause line running on the same account as the weight program.
Visit Gala HealthThe verdict
NextMeds takes it, leading the Cost-Efficiency Index 74 to 71. NextMeds is a compounded-GLP-1 telehealth platform naming a real clinical group (Lion MD, led by two NPI-verifiable physicians) and six named compounding pharmacies — unusually transparent on that front. Gala Health still earns a C — Women who have already committed to a full year and want one all-doses-included rate — plus, unusually, an HRT and menopause line running on the same account as the weight program.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs NextMeds.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | NextMeds | Gala Health |
|---|---|---|
| Cost-Efficiency Index | 74/100 | 71/100 |
| Semaglutide / mo | $79/mo (starting dose, promotional rate, compounded) | No compounded option — brand Ozempic only, $1,299/mo |
| Tirzepatide / mo | $129/mo (starting dose, promotional rate, compounded) | $179/mo (yearly subscription; $199/mo on a 3-month plan) |
| Semaglutide / yr (modeled) | $948 | — |
| Tirzepatide / yr (modeled) | $1,548 | $2,148 |
| Coverage | All 50 states | 50 states claimed, no list published |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Yes |
| Rank here | #61 | #63 |
NextMeds
74/100Where the value is
- Names a real, NPI-verifiable clinical group (Lion MD: Dr. Ana Lisa Carr, Dr. Kelly Tenbrink) rather than an anonymous provider network
- Names six real compounding pharmacies (Belmar, Strive, Epiq Scripts, Casa Pharma Rx, The Pharmacy Hub, Foothills) instead of one generic claim
- Claims and states 'We service all 50 states'
The tradeoffs
- The live site shows at least three different headline promo prices ($69/$79/$89 for semaglutide) concurrently or near-concurrently, with no clear single 'current' number — a real transparency problem
- Aggressive countdown-timer urgency tactics ('Price increases in...', 'OFFER ENDS AUGUST 10TH AT MIDNIGHT!') are used to pressure signup
Gala Health
71/100Where the value is
- $179/mo on a yearly subscription, with every dose included, so the price does not climb as you titrate — dose escalation is where most flat-looking programs quietly get expensive
- The price list is PUBLIC and un-gated: the weight tier, the $149 microdosing tier and the brand tier are all printed before any quiz, intake or email capture
- Both compounded molecules — semaglutide and tirzepatide — prescribable on one account
The tradeoffs
- No month-to-month price exists anywhere on the site. "FROM $179/month" sits directly above "All doses included. Yearly subscription.", and the cheapest alternative the FAQ names is "$199 per month (with a 3-month plan)" — three months is the shortest published commitment there is
- $179/mo is $2,148 committed for the year, and that total is printed nowhere: the site quotes a monthly figure for a purchase it only sells annually, which is the single hardest cost in this ranking to compare against a rate you can cancel next month
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.